{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:58:41Z","timestamp":1792616321797,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis [PSC] in patients with inflammatory bowel disease [IBD] remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective observational study of consecutive patients with IBD and PSC, treated with vedolizumab for at least 30 weeks in 22 centres of GETAID from January 2015 to June 2016. The outcomes included a decrease in the serum alkaline phosphatase [ALP] concentration of at least 50% from baseline to Week 30 or 54, a change in any serum liver enzymes concentrations, and an assessment of the efficacy and safety of vedolizumab in IBD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 75 patients with active IBD and PSC treated with vedolizumab, 21 patients discontinued vedolizumab before Week 30 [due to lack of efficacy in 19 and malignancy in two patients]. In the remaining 54 patients, a decrease in the serum ALP concentration of at least 50% from baseline to Weeks 30 and 54 was observed in four [7%] and four [11%] patients, respectively. No significant change was observed in serum liver enzyme concentrations at week 30 or 54. After a median follow-up period of 19.4 [14.0\u201329.9] months, nine cases of digestive neoplasia [colorectal neoplasia in seven and cholangiocarcinoma in two] were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with IBD and PSC, vedolizumab did not improve serum liver enzyme concentrations at week 30 or 54. Nine cases of digestive cancer occurred during the follow-up period, confirming the need for a tight surveillance programme in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz088","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T23:15:17Z","timestamp":1556752517000},"page":"1239-1247","source":"Crossref","is-referenced-by-count":57,"title":["Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"given":"Benedicte","family":"Caron","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, H\u00f4pitaux Universitaires de Strasbourg [H\u00f4pital de Hautepierre] and INSERM U1113 IRFAC, Universit\u00e9 de Strasbourg [Facult\u00e9 de M\u00e9decine], Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"INSERM U954 and Department of Gastroenterology, Universit\u00e9 de Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pariente","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Huriez Hospital, Universit\u00e9 of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, University Paris 7 Denis Diderot, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, AP-HP, H\u00f4pital Saint-Antoine, ERL 1057 INSERM\/UMRS 7203, UPMC Universit\u00e9 Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pontchaillou Hospital and Rennes University, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Caillo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nimes University Hospital, Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital of Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bicetre University Hospital, APHP, Universit\u00e9 Paris Sud, le Kremlin Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, H\u00f4pital Saint-Eloi, University Hospital of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reenaers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liege University Hospital, Liege, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"H\u00f4pital Nord, Centre d\u2019investigation clinique Marseille Nord, Universit\u00e9 M\u00e9diterran\u00e9e, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Trang-Poisson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institut des Maladies de l\u2019appareil Digestif [IMAD], University Hospital of Nantes, Nantes University, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Pierre-Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Filippi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, Nice University Hospital, University of Nice Sophia-Antipolis, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cochin Hospital, University Paris 5 Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Savoye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rouen University and Hospital, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Viennot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Caen University Hospital, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Reymond","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital Estaing of Clermont-Ferrand, Universit\u00e9 d\u2019Auvergne, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[{"name":"INSERM U954 and Department of Gastroenterology, Universit\u00e9 de Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Reimund","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, H\u00f4pitaux Universitaires de Strasbourg [H\u00f4pital de Hautepierre] and INSERM U1113 IRFAC, Universit\u00e9 de Strasbourg [Facult\u00e9 de M\u00e9decine], Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Amiot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Henri Mondor Hospital, APHP, EC2M3-EA7375, Paris Est-Cr\u00e9teil Val de Marne University, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"2019100421363092000_CIT0001","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"2019100421363092000_CIT0002","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"key":"2019100421363092000_CIT0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2036.2011.04753.x","article-title":"Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"34","author":"Torres","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2019100421363092000_CIT0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"2019100421363092000_CIT0005","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019100421363092000_CIT0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","author":"Burak","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2019100421363092000_CIT0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1478-3231.1999.tb00084.x","article-title":"Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease","volume":"19","author":"Hillan","year":"1999","journal-title":"Liver"},{"key":"2019100421363092000_CIT0008","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","article-title":"Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease","volume":"359","author":"Grant","year":"2002","journal-title":"Lancet"},{"key":"2019100421363092000_CIT0009","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium [MAdCAM-1 in chronic inflammatory liver disease]","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"2019100421363092000_CIT0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J Exp Med"},{"key":"2019100421363092000_CIT0011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2009.02.046","article-title":"Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells","volume":"137","author":"Eksteen","year":"2009","journal-title":"Gastroenterology"},{"key":"2019100421363092000_CIT0012","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"2019100421363092000_CIT0013","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019100421363092000_CIT0014","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019100421363092000_CIT0015","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"2019100421363092000_CIT0016","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2019100421363092000_CIT0017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2019100421363092000_CIT0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019100421363092000_CIT0019","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2019100421363092000_CIT0020","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"2019100421363092000_CIT0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11894-015-0438-0","article-title":"Screening for malignancy in primary sclerosing cholangitis [PSC]","volume":"17","author":"Khaderi","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"2019100421363092000_CIT0022","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019100421363092000_CIT0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz088\/28658963\/jjz088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/10\/1239\/30104618\/jjz088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/13\/10\/1239\/30104618\/jjz088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T21:36:43Z","timestamp":1570225003000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/13\/10\/1239\/5485858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5,6]]},"published-print":{"date-parts":[[2019,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz088","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,5,6]]}}}